## **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM S-1 REGISTRATION STATEMENT

**UNDER** THE SECURITIES ACT OF 1933

# BioAtla, Inc.

(Exact name of Registrant as specified in its charter)

Delaware			
(State or other jurisdiction of			
incorporation or organization)			

(Primary Standard Industrial

85-1922320 (I.R.S. Employer Identification Number)

11085 Torreyana Road San Diego, California 92121 (858) 558-0708

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

Jay M. Short, Ph.D. **Chairman and Chief Executive Officer** BioAtla, Inc.

	11085 Torro San Diego, Ca (858) 55 (Name, address, including zip code, and telephone	lifornia 92121 8-0708	
	Copi	es to:	
V	David Schulman, Esq. David Rosenthal, Esq. Dechert LLP 1900 K Street, N.W. Washington, D.C 20006-1110 (202) 261-3300	William Fogg, Esq. Michael Mariani, Esq. Cravath, Swaine & Moore LLP Worldwide Plaza 825 Eighth Avenue New York, NY 10019 (212) 474-1000	
<b>Approximate dat</b> effective.	e of commencement of proposed sale to the public	: As soon as practicable after this Registration Statement becomes	
If any of the secur Act of 1933, check the f		on a delayed or continuous basis pursuant to Rule 415 under the Securities	!S
		uant to Rule 462(b) under the Securities Act, please check the following fective registration statement for the same offering. ⊠ (333-250093)	
•	ost-effective amendment filed pursuant to Rule 462( nt number of the earlier effective registration stateme	c) under the Securities Act, check the following box and list the Securitient for the same offering. $\square$	S
•	ost-effective amendment filed pursuant to Rule 462( nt number of the earlier effective registration stateme	d) under the Securities Act, check the following box and list the Securitient for the same offering. $\square$	!S
or an emerging growth c		er, an accelerated filer, a non-accelerated filer, a smaller reporting compacer," "accelerated filer," "smaller reporting company," and "emerging grown"	
Large accelerated filer		Accelerated filer	
Non-accelerated filer	$\boxtimes$	Smaller reporting company	X
		Emerging growth company	X
	owth company, indicate by check mark if the registra	nt has elected not to use the extended transition period for complying with $(2)(R)$ of the Securities $A$ of $R$	:h

		Proposed Maximum	Proposed Maximum	
	Amount to be	Aggregate Offering	Aggregate Offering	Amount of
Title of Each Class of Securities to be Registered	Registered(1)	Price Per Share	Price	Registration Fee(2)(3)
Common Stock, \$0.0001 par value per share	1,265,000	\$18.00	\$22,770,000	\$2,484.21

- (1) Represents only the additional number of shares being registered and includes 165,000 additional shares of common stock that the underwriters have the option to purchase. Does not include the securities that the Registrant previously registered on the Registration Statement on Form S-1 (File No. 333-250093).
- (2) The registration fee is calculated in accordance with Rule 457(a) under the Securities Act of 1933, as amended, based on the proposed maximum aggregate offering price.
- (3) The registrant previously registered 10,810,000 shares of its common stock with an aggregate offering price not to exceed \$183,770,000 on a Registration Statement on Form S-1 (File No. 333-250093), which was declared effective by the Securities and Exchange Commission on December 15, 2020. In accordance with Rule 462(b) under the Securities Act, as amended, an additional amount of securities having a proposed maximum aggregate offering price of \$22,770,000 are hereby registered, which includes shares issuable upon the exercise of the underwriters' option to purchase additional shares.

This Registration Statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

#### **EXPLANATORY NOTE AND INCORPORATION BY REFERENCE**

This Registration Statement on Form S-1 (this "Registration Statement") is being filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, for the sole purpose of increasing the aggregate number of shares of common stock offered by BioAtla, Inc. (the "Registrant") by 1,265,000 shares, 165,000 of which are subject to purchase upon exercise of the underwriters' option to purchase additional shares of the Registrant's common stock. The additional securities that are being registered for sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price set forth in the Calculation of Registration Fee table contained in the Registration Statement on Form S-1, as amended (File No. 333-250093) (the "Prior Registration Statement"). The information set forth in the Prior Registration Statement and all exhibits thereto are hereby incorporated by reference in this filing.

The required opinion and consents are listed on an Exhibit Index attached hereto and filed herewith.

## EXHIBIT INDEX

Exhibit <u>Number</u>	<u>Description</u>
5.1	Opinion of Dechert LLP
23.1	Consent of Independent Registered Public Accounting Firm
23.2	Consent of Dechert LLP (included in Exhibit 5.1)
24.1	Power of Attorney (included on page II-8 of the Registration Statement on Form S-1 (File No. 333-250093), filed with the Securities and Exchange Commission on November 13, 2020 and December 8, 2020 and incorporated herein by reference)

#### **Signatures**

Pursuant to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on the 15th day of December, 2020.

## BIOATLA, INC.

By: /s/ Jay M. Short

Jay M. Short, Ph.D. Chief Executive Officer

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Jay M. Short Jay M. Short, Ph.D.	Chief Executive Officer and Director (Principal Executive Officer)	December 15, 2020
/s/ Richard A. Waldron Richard A. Waldron	Chief Financial Officer (Principal Financial and Accounting Officer)	December 15, 2020
* Scott Smith	President and Director	December 15, 2020
* Priyanka Belawat, Ph.D.	Director	December 15, 2020
* Guy Levy	Director	December 15, 2020
* Lawrence Steinman	Director	December 15, 2020
* Mary Ann Gray, Ph.D.	Director	December 15, 2020
* Susan Moran, M.D.	Director	December 15, 2020
*By: /s/ Jay M. Short  Jay M. Short, Ph.D. Attorney-in-Fact		



1095 Avenue of the Americas New York, NY 10036-6797 +1 212 698 3500 Main +1 212 698 3599 Fax www.dechert.com

December 15, 2020

BioAtla, Inc. 11085 Torreyana Road San Diego, California 92121

#### Re: <u>REGISTRATION STATEMENT ON FORM S-1</u>

#### Ladies and Gentlemen:

We have acted as counsel to BioAtla, Inc. a Delaware corporation (the "<u>Company</u>"), in connection with the filing with the Securities and Exchange Commission (the "<u>Commission</u>") of a Registration Statement on Form S-1 (the "<u>Registration Statement</u>") pursuant to Rule 462(b) of Regulation C promulgated under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), covering an underwritten public offering of up to 1,265,000 shares of the Company's common stock, par value \$0.0001 per share, all of which will be sold by the Company (the "<u>Securities</u>"), and which includes up to 165,000 shares that may be sold pursuant to the exercise of an option to purchase additional shares. The Registration Statement incorporates by reference the Registration Statement on Form S-1 (File No. 333-250093), which was declared effective on December 15, 2020 (the "<u>Prior Registration Statement</u>"), including the prospectus which forms a part of the Prior Registration Statement.

This opinion (the "Opinion") is being furnished to the Company in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement other than as expressly stated herein with respect to the Securities.

As your counsel, we have examined such documents and such matters of fact and law that we have deemed necessary for the purpose of rendering the Opinion expressed herein. In our examination, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as original documents, and the conformity to original documents of all documents submitted to us as copies, the legal capacity of natural persons who are signatories to the documents examined by us, and the legal power and authority of all persons signing on behalf of parties (other than the Company) to all documents.

Based on the foregoing, we advise you that, in our opinion, when the Securities have been duly issued and delivered against payment therefor in accordance with the



BioAtla, Inc. December 15, 2020 Page 2

terms of the Underwriting Agreement referred to in the prospectus that is a part of the Prior Registration Statement, the Securities will be validly issued, fully paid and non-assessable.

We are members of the Bar of the State of New York and the foregoing Opinion is limited to the General Corporation Law of the State of Delaware.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and further consent to the reference to our name under the caption "Legal Matters" in the prospectus that is a part of the Prior Registration Statement, which is incorporated by reference into the Registration Statement. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

Very truly yours,

/s/ Dechert LLP

#### **Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement on Form S-1 filed pursuant to Rule 462(b) of the Securities Act of 1933 of the reference to our firm under the caption "Experts" and to the incorporation by reference of our report dated October 5, 2020 (except for the last paragraph of Note 12, as to which the date is December 8, 2020), with respect to the consolidated financial statements of BioAtla, Inc. included in Amendment No. 2 to the Registration Statement (Form S-1 No. 333-250093) and related Prospectus of BioAtla, Inc. for the registration of its common stock.

/s/ Ernst & Young LLP

San Diego, California December 15, 2020